Observational studyPloS one2023
Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique.
Observational study in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Environmental endocrine disruptors and endometrial cancer: a systematic review of epidemiological studies.Frontiers in endocrinology · 2026Pooled it
- Safety of diagnostic hysteroscopy for the investigation of type II endometrial cancer: systematic review with meta-analysis.BMJ open · 2024Pooled it
- Fifteen-year trends in cancer incidence and mortality among older adults aged 65 years and older in Martinique, a Caribbean population-based registry study, 2008-2022.Scientific reports · 2026Article
- IHC analysis of estrogen receptor (ER) and progesterone receptor (PR) expression in endometrial carcinomas.Irish journal of medical science · 2026Article
- Feasibility ofCancers · 2026Article
- Histopathology Images-Based Deep Learning Prediction of Histological Types in Endometrial Cancer.Cancer medicine · 2026Article
- Molecular profiling of endometrial cancer in Martinique reveals frequent CCNE1 amplification in poor prognosis tumors.Scientific reports · 2025Article
- Association of ZWINT Expression with Clinicopathologic Characteristics and Prognosis in Breast Cancer Patients.Current medical science · 2025Article
- Establishment and validation of a prognostic nomogram for overall survival in type II endometrial carcinoma patients.Scientific reports · 2025Article
- Immune alterations and overexpression of CTCF in endometrial carcinoma: insights from molecular subtyping.Cancer cell international · 2024Article
- Single-cell transcriptome profiles the heterogeneity of tumor cells and microenvironments for different pathological endometrial cancer and identifies specific sensitive drugs.Cell death & disease · 2024Article
- Copy number signatures and CCNE1 amplification reveal the involvement of replication stress in high-grade endometrial tumors oncogenesis.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- The Deep Proteomics Approach Identified Extracellular Vesicular Proteins Correlated to Extracellular Matrix in Type One and Two Endometrial Cancer.International journal of molecular sciences · 2024Article
- Review
- Clinicopathological characteristics of endometrial carcinoma with different molecular subtypes and their correlation with lymph node metastasis.American journal of cancer research · 2024Article
- Comparison of clinical characteristics and prognosis between type I and type II endometrial cancer: a single-center retrospective study.Discover oncology · 2023Article
- Comparison of clinical characteristics and prognosis in endometrial carcinoma with different pathological types: a retrospective population-based study.World journal of surgical oncology · 2023Article
- Convention Smears of Pleural Effusion Cytology Revealing Metastatic Clear Cell Carcinoma of Endometrium: A Rare Case Report and Review of Literature.Journal of cytologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND STUDY
aimsIn Martinique, about 33 new cases of endometrial cancer are diagnosed per year with a high mortality rate (world standardised rate of 4.9/100,000 versus 2.3/100,000 in mainland France). The present study aimed to determine the incidence and mortality of type I and type II endometrial cancers (ECs), their overall survival (OS) and disease-free survival (DFS) between 2012 and 2016. PATIENTS AND
methodsThis retrospective observational cohort study used data from the Martinique Cancer Registry (MCR). 191 patients with corpus uterine cancer were extracted between 2012 and 2016. Patients with either endometrioid endometrial carcinoma (EEC), uterine papillary serous carcinomas (UPSC), uterine clear cell carcinomas (UCCC) or uterine carcinosarcomas (UCS) were included. All other uterine cancers were excluded.
resultsAmong the 163 included patients, 97 (60%) were type I and 66 (40%) were type II. The standardized incidence rate is 4.50/100,000 for type I vs. 2.66/100,000 for type II. Three years DFS for all types, type I and type II was 81.5% [74.2-86.9], 84.9% [75.4-91] and 76.7% [63.8-85.5] respectively. The five-years OS for all types, type I and type II was 47.0% [38.9-54.7] vs. 58.8% [47.3-68.5] vs. 22.8% [15.0-37.7] respectively.
conclusionsIn Martinique, we report a high proportion of type II ECs, which has a poor prognosis with few treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.